Consulting and Fee Agreement between Medgenics, Inc. and Equity Source Partners, LLC

Summary

Medgenics, Inc. and Equity Source Partners, LLC entered into an agreement where Equity Source Partners introduced specific investors to Medgenics for its private placement of convertible notes and warrants. In return, Medgenics agreed to pay Equity Source Partners a cash finder’s fee based on a set percentage of the investment amount from each introduced investor. The agreement lists the investors and their respective fee percentages, and requires payment of the fees promptly after the closing of the private offering.

EX-10.39 62 v200830_ex10-39.htm CONSULTING AND FEE AGREEMENT
 
 
EXHIBIT 10.39
Equity Source Partners, LLC 
7 East Carver Street                
Huntington, New York 11743

September 15, 2010

Medgenics, Inc.
8000 Towers Crescent Drive
Suite 1070
Vienna, Va. 22182
Attention: Dr. Andrew Pearlman, President

Dear Andy:

As per our earlier discussions I am writing to confirm the agreement between Medgenics, Inc. (“Medgenics”) and Equity Source Partners (“ESP”) regarding our introduction to Medgenics of certain investors in Medgenics’ current private placement of convertible notes and related warrants (the “Private Offering”).

Medgenics has asked that we have introduced you to, or facilitated the introduction of, certain individuals and their entities listed below, and that, in consideration for such introductions, the Company has agreed to pay ESP a cash finder’s fee equal to an agreed percentage (as set forth below) of the aggregate original principal amount of the Notes purchased by each such investor in the Private Offering.

Isaac Blech (or his entities)
2%
Iroquois Capital
5%
Chestnut Ridge
5%
Kingsbrook Partners
5%

Payment of the finder’s fees shall be made promptly after the closing of the Private Offering. Your signature below indicates your agreement to these terms as of the date above.
 
Best regards,
 
Agreed to:
     
/s/ Cary Sucoff
 
/s/ Andrew Pearlman
Cary Sucoff
 
Andrew Pearlman
Equity Source Partners LLC
 
Medgenics, Inc.